D4-Chip揭示脓毒症T细胞功能受损:血浆微环境分析与线粒体靶向治疗的启示
该研究利用D4-Chip微流控平台评估脓毒症患者T细胞的迁移功能,并探讨血浆微环境和氧化还原环境的影响。结果显示脓毒症T细胞迁移功能较健康对照受损;脓毒症血浆可增强健康T细胞迁移,但健康血浆孵育不能完全恢复脓毒症T细胞的迁移缺陷。脓毒症T细胞内NADH/NAD+水平显著升高,健康T细胞暴露于脓毒症血浆后NADH/NAD+亦升高。线粒体靶向药物MitoQ可纠正异常NADH/NAD+水平并增强T细胞迁移能力,提示改善细胞内氧化还原环境有助于恢复脓毒症T细胞功能。
要点
- 脓毒症患者T细胞迁移功能较健康对照受损,D4-Chip微流控平台可在可控条件下精确分析迁移功能。
- 脓毒症血浆孵育可增强健康T细胞迁移,但健康血浆孵育不能完全恢复脓毒症T细胞的迁移缺陷。
- 脓毒症T细胞内NADH/NAD+水平显著升高,健康T细胞暴露于脓毒症血浆后NADH/NAD+亦升高。
- MitoQ可纠正脓毒症T细胞异常升高的NADH/NAD+水平并增强其迁移能力。
- 短期脓毒症血浆孵育不直接抑制T细胞迁移,而是通过破坏细胞内氧化还原环境影响T细胞功能。
适用人群与场景
- 脓毒症患者T细胞与健康对照T细胞
- 体外实验:健康T细胞暴露于脓毒症血浆
处置流程与药物剂量
- MitoQ(甲磺酸米托醌)在体外实验中被用于纠正脓毒症T细胞异常升高的NADH/NAD+水平并增强T细胞迁移能力,原文未报告具体剂量、途径与疗程。
研究设计与关键结果
- 研究开发D4-Chip微流控平台评估脓毒症T细胞迁移功能,发现脓毒症T细胞迁移功能较健康对照受损。
- 脓毒症血浆增强健康T细胞迁移,但健康血浆孵育不能完全恢复脓毒症T细胞的迁移缺陷。
- 脓毒症T细胞NADH/NAD+水平显著升高;健康T细胞暴露于多种脓毒症血浆条件后NADH/NAD+水平亦升高。
- MitoQ使脓毒症T细胞异常升高的NADH/NAD+水平恢复正常并增强T细胞迁移能力。
证据类型、等级与局限
- 证据类型:体外实验研究(D4-Chip微流控平台分析脓毒症患者T细胞与健康对照T细胞,以及健康T细胞暴露于脓毒症血浆的体外实验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,短期脓毒症血浆孵育不直接抑制T细胞迁移,而是通过破坏细胞内氧化还原环境影响T细胞功能。
- 作者认为,改善脓毒症患者细胞内氧化还原环境有助于恢复受损的迁移与增殖功能。
- 作者认为,MitoQ显示出治疗潜力。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Sepsis, a systemic inflammation syndrome initiated by infection, poses significant challenges due to its intricate pathophysiology. T cells play a crucial role in combating infections during sepsis. Despite previous observations indicating T-cell dysfunction in sepsis, reliable in vitro detection methods were lacking, and the factors influencing these impairments remained unclear. Methods: We developed a novel method using the D 4 -Chip to assess sepsis T-cell migration function. This microfluidic platform enabled precise analysis of migration function under controlled conditions. Additionally, We explored the impact of the plasma microenvironment on T-cell behavior, along with the redox environment in sepsis, and assessed the potential efficacy of Mitoquinone mesylate (MitoQ), a mitochondrial-targeted drug. Results: Our findings revealed impaired migration function in sepsis T cells compared to healthy controls. Interestingly, sepsis plasma enhanced the migration of healthy T cells, yet incubation with healthy plasma did not fully restore migration impairments in sepsis T cells. Subsequent investigations uncovered a significant increase in NADH/NAD+ levels in sepsis T cells, with healthy T cells exposed to various sepsis plasma conditions also showing elevated NADH/NAD+ levels. Importantly, MitoQ normalized abnormal intracellular NADH/NAD+ levels and enhanced the migration ability of T cells. Conclusions: Short-term incubation with sepsis plasma does not directly inhibit T-cell migration but instead affects T-cell function by disrupting the intracellular redox environment. Improving the intracellular redox environment of sepsis patients contributes to restoring impaired migration and proliferation, with MitoQ demonstrating therapeutic potential.
参考来源
- Liu L, Wang R, Pu X, et al. D 4 -CHIP REVEALS IMPAIRED T-CELL FUNCTION IN SEPSIS: INSIGHTS FROM PLASMA MICROENVIRONMENT ANALYSIS AND MITOCHONDRIAL-TARGETED THERAPY. Shock. 2024. PMID: 39178197. doi:10.1097/SHK.0000000000002434
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。